Transplant Diagnostics Global Market 2019-2023 with Thermo Fisher Scientific, Inc, Bio-Rad Laboratories, Inc., F. Hoffman-La Roche Ltd, Becton Dickinson and Company, Abbott Laboratories Inc Etc.

Global Transplant Diagnostics Market – Key Players

Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), Becton Dickinson and Company (US), Abbott Laboratories Inc (US), CareDx (US), QIAGEN N.V. (Netherlands), Immucor, Inc. (US), GenDx (Netherlands), Omixon Ltd. (UK), bioMérieux S.A. (France), Illumina, Inc. (US), Immucor Transplant Diagnostics, Inc (US), Affymetrix, Inc (US), Linkage Biosciences (US)

Global Transplant Diagnostics Market – Segmentation

The Market for Transplant Diagnostics is segmented on the basis of products into reagent, instrument, software and services. The technology basis of segmentation of the market includes molecular assay and non-molecular assay. The non-molecular segment is further segmented into mixed lymphocyte culture and serological assay. The molecular assay segment is additionally segmented into PCR based and sequenced base. The application-based segment of the market consists of kidney, lungs, heart, liver, and other. On the basis of method type, the market comprises of post-transplant screening and pre-transplant screening. Finally, the end user segmentation consists of transplants centers, hospitals, research laboratories and other.

Get Sample Report @ https://www.marketresearchfuture.com/sample_request/1324

Global Transplant Diagnostics Market – Highlights

Market concentrated reports associated with the healthcare industry amid others recently have been made available by Market Research Future which issues reports on this industry. The Market for Transplant Diagnostics is expected to develop at an encouraging CAGR of 7.2% in the duration of the forecast period. Transplant surgeries have observed a significant uptick in recent years due to increased detection of diseases that lead to organ failure. This development has increased the growth rate experienced by transplant diagnostics.

The escalation in the detection of chronic diseases has increased the need to test whether the recipients can accept the transplant easily in case transplants are required. Lungs, liver, kidney are among the most commonly donated organs that have to be tested for compatibility with the host body. Diseases such as diabetes, renal failures, and coronary heart diseases are among a few of the chief causes fueling the growth of the transplant diagnostic market at an increased pace. However, increased cost of transplants and lack of access to high quality medical resources is expected to restrain the market’s growth in the forecast period.

Industry Updates:

In May 2018, CareDx, a U.S.-based molecular diagnostics company, has announced the signing of licensing and commercialization agreement with Illumina, a provider of next-generation sequencing solutions. CareDx is now the exclusive worldwide distributor of Illumina’s TruSight HLA v1 and v2 product lines which will be used for bone marrow transplantation diagnostic testing and solid organ transplantation diagnostic testing.

TAI Diagnostics which is US based company and develops non-invasive test to monitor patients’ health after they’ve got heart transplants, has scheduled to initiate selling their test early next year. They have generated about $13 million from their investors so far. The company is presently raising more money to supplement its $8.3 million Series A funding round. The extension could bring TAI’s total outside financing to $21 million, the startup’s test measures levels of cell-free DNA, genetic material released by the transplant recipient’s new heart that can enter the bloodstream, to assess whether they are in danger of rejecting the organ.

Thermo Fisher Scientific Acquires Linkage Bio: on July 2017 Thermo Fisher Scientific confirmed the company's acquisition of Linkage Biosciences for an undisclosed amount, as a result of this acquisition Linkage Biosciences is now a part of Thermo Fisher's transplant diagnostics business. The company based in South San Francisco, California. Benefits involved from the acquisition include a broader and deeper range of products, a continued commitment to innovation, and expanded support globally.

The business is extremely complementary to the company's One Lambda tests, which regulate the compatibility of donors and recipients pre- and post-transplant. This acquisition further expands Thermo Fisher's commitment of improving transplant patients' quality of life over innovative high-quality products for the clinical and research segments of the transplant community.

Browse Complete 100 Pages Premium Research Report Enabled with Tables and Figures @ https://www.marketresearchfuture.com/reports/transplant-diagnostics-market-1324

Global Transplant Diagnostics Market - Regional Analysis

Geographically, America dominated the global transplant diagnostics market. Increasing demand for the advanced techniques and diagnostic tools and higher healthcare expenditure are the major factor for the growth of the America market. Europe is the second largest transplant diagnostics market which is followed by Asia Pacific. Asia pacific is the fastest growing region for this market. Large population pole suffering from chronic diseases is the major driving factor for the Asia Pacific market.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@marketresearchfuture.com

This release was published on openPR.